20
Fermion Oy, based in Finland, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for With Fermion, start the journey of your innovative API.
One of their notable products is CARBIDOPA, with a corresponding US DMF Number 26416.
Remarkably, this DMF maintains an Active status since its submission on September 14, 2012, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of November 20, 2013, and payment made on May 10, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II